BX2 Stock Overview
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
BioXcel Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$2.62 |
52 Week High | US$27.60 |
52 Week Low | US$1.83 |
Beta | 0.42 |
1 Month Change | -6.95% |
3 Month Change | 0.61% |
1 Year Change | -83.72% |
3 Year Change | -92.42% |
5 Year Change | -66.66% |
Change since IPO | -67.20% |
Recent News & Updates
Recent updates
Shareholder Returns
BX2 | DE Biotechs | DE Market | |
---|---|---|---|
7D | 7.8% | 2.1% | 1.9% |
1Y | -83.7% | 37.0% | 7.3% |
Return vs Industry: BX2 underperformed the German Biotechs industry which returned 37% over the past year.
Return vs Market: BX2 underperformed the German Market which returned 7.3% over the past year.
Price Volatility
BX2 volatility | |
---|---|
BX2 Average Weekly Movement | 20.4% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BX2's share price has been volatile over the past 3 months.
Volatility Over Time: BX2's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 74 | Vimal Mehta | https://www.bioxceltherapeutics.com |
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
BioXcel Therapeutics, Inc. Fundamentals Summary
BX2 fundamental statistics | |
---|---|
Market cap | €81.34m |
Earnings (TTM) | -€165.39m |
Revenue (TTM) | €1.27m |
63.8x
P/S Ratio-0.5x
P/E RatioIs BX2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BX2 income statement (TTM) | |
---|---|
Revenue | US$1.38m |
Cost of Revenue | US$1.26m |
Gross Profit | US$120.00k |
Other Expenses | US$179.17m |
Earnings | -US$179.05m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -5.86 |
Gross Margin | 8.70% |
Net Profit Margin | -12,974.86% |
Debt/Equity Ratio | -178.0% |
How did BX2 perform over the long term?
See historical performance and comparison